Log in

Medmen Enterprises Stock Forecast, Price & News

-0.01 (-6.03 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $0.16
50-Day Range
MA: $0.17
52-Week Range
Now: $0.16
Volume6.64 million shs
Average Volume2.25 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, and distributes, and retails recreational and medicinal cannabis. As of November 1, 2018, it had licenses for 69 retail stores; and 17 cultivation and production facilities across 12 states. The company is headquartered in Culver City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
-0.01 (-6.03 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MMNFF News and Ratings via Email

Sign-up to receive the latest news and ratings for MMNFF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Medmen Enterprises (OTCMKTS:MMNFF) Frequently Asked Questions

How has Medmen Enterprises' stock price been impacted by Coronavirus?

Medmen Enterprises' stock was trading at $0.1539 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MMNFF shares have increased by 1.3% and is now trading at $0.1559.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Medmen Enterprises?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medmen Enterprises in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medmen Enterprises

What price target have analysts set for MMNFF?

4 brokerages have issued 1-year target prices for Medmen Enterprises' stock. Their forecasts range from $0.75 to $4.00. On average, they anticipate Medmen Enterprises' share price to reach $2.38 in the next year. This suggests a possible upside of 1,423.4% from the stock's current price.
View analysts' price targets for Medmen Enterprises

Are investors shorting Medmen Enterprises?

Medmen Enterprises saw a decrease in short interest in August. As of August 31st, there was short interest totaling 7,713,800 shares, a decrease of 16.2% from the August 15th total of 9,206,000 shares. Based on an average daily volume of 2,243,300 shares, the days-to-cover ratio is presently 3.4 days.
View Medmen Enterprises' Short Interest

Who are some of Medmen Enterprises' key competitors?

Who are Medmen Enterprises' key executives?

Medmen Enterprises' management team includes the following people:
  • Mr. Adam Bierman, Co-Founder, CEO & Director (Age 38)
  • Mr. Andrew Modlin, Co-Founder, Pres & Director (Age 32)
  • Mr. Michael W. Kramer, Chief Financial Officer (Age 55)
  • Mr. James Miller, VP of Accounting (Age 59)
  • Mr. Ryan Lissack, Chief Technology Officer

What is Medmen Enterprises' stock symbol?

Medmen Enterprises trades on the OTCMKTS under the ticker symbol "MMNFF."

How do I buy shares of Medmen Enterprises?

Shares of MMNFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medmen Enterprises' stock price today?

One share of MMNFF stock can currently be purchased for approximately $0.16.

What is Medmen Enterprises' official website?

The official website for Medmen Enterprises is www.medmen.com.

How can I contact Medmen Enterprises?

The company can be reached via phone at 855-292-8399.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.